The sentence first came at a routine physical and has returned at nearly every visit since: “Watch your diet and get more exercise.” You took it seriously. You logged meals, walked before work and kept the gym membership long past January. The weight came off slowly and came back quickly. Somewhere in the second half of the decade, without telling anyone, you decided the problem was your discipline.

The person described here is a composite. No real patient's story is told. The pattern is common enough to name all the same. It is a decade of the same advice with fasting insulin never tested once. That is a gap in the workup. It says nothing about your effort. Now a $99-a-month app offers a prescription in a few clicks. The fair question is whether that app is the same thing as a clinician who measures first.

GoodLife Health measures fasting insulin before glucose turns abnormal. A clinician then treats what the results show. This piece sets that model beside the $99 app, with year-one figures for both sides and a date on every price. It also says plainly who should choose the app.

Key Takeaways
  • A decade of advice without a fasting insulin draw points to a missing test.
  • GoodLife Health measures fasting insulin before glucose turns abnormal and reads it beside Hemoglobin A1c (HbA1c) every quarter.
  • The $99 on the advert is a platform fee. With a compounded drug added, one such platform came to $298 to $398 a month (August 2026).
  • The membership is $299 a month or $3,588 a year, with any medication billed by your own pharmacy at its price.
  • A compounded-only subscription ran $3,600 to $6,000 in year one with no labs in the fee (September 2026).
  • When the drug is the expensive part, the prescriber should earn nothing on it. GoodLife Health takes nothing.

A decade of the same advice

Most people in this situation can reconstruct the record from memory. There was a basic panel at the annual visit. The fasting glucose came back inside the range, sometimes near the top of it. Someone read a cholesterol number aloud and moved on. The advice filled most of an eight-minute visit. The next appointment was a year away.

What was usually missing is the part that might have explained the decade. Fasting insulin was not on the order. Nobody followed any marker from one season to the next, since a model built on one annual visit has no seasons in it. Each result was read against a population range. Normal is a population range. You are one person.

None of this requires a villain. A clinician with a full schedule and a short appointment works from what the visit allows. Advice to eat better and move more is rarely wrong as advice. The failure is structural. A model with no room for a second draw cannot tell anyone whether the first piece of advice did anything. So the advice repeats itself, year after year, at the same length.

When advice fails for long enough, people stop blaming the advice. They keep the scale in a cupboard. They turn down the second helping in public and feel judged anyway. They stop raising the subject at appointments because they already know what they will hear. That quiet conclusion costs more than anything else in the decade. It ends the search for a cause.

Then the advert arrives. A $99-a-month app offers a GLP-1 prescription after an online questionnaire, often with no labs required. For someone dismissed for 10 years, any clinician who takes the weight seriously feels like progress. The price looks like the easy part.

The objection deserves a straight answer. If the app writes a prescription and the membership writes a prescription, why pay $299 for what looks like the same thing? The answer turns on two questions. What happens before the prescription is written? Who earns money once it is?

What the advice never measured

Fasting insulin can rise for years before fasting glucose moves. A panel that checks glucose alone can therefore come back normal through that whole stretch. The result was accurate. It was answering a narrower question than the one your decade was asking.

Our guide to the real cost of a $299 membership puts the consequence in one line. Untreated insulin resistance, hormone decline and weight gain can compound for a decade before a diagnosis. That describes the record most readers in this situation already hold. It also changes how the decade reads. Advice given without the measurement could never show whether it was working. Nobody can judge a decade of effort against a number nobody drew.

Nobody can judge a decade of effort against a number nobody drew.

This is also why one more normal result rarely settles anything. A single draw shows where a marker sat on one morning. A series shows which way it is moving. For most of the last decade, the word normal described where your number fell in a range. Nobody looked at the direction of your own numbers from one draw to the next.

The $99 app is built around a different order of work. Our pricing guides describe the model plainly. GLP-1 subscription telehealth advertises a low fee and recovers its margin on the drug. In our August 2026 comparison of GLP-1 telehealth costs, one $99-a-month platform came to $298 to $398 a month once compounded semaglutide or liraglutide was added. The advertised number was real. It was the platform fee alone.

When revenue arrives with the medication, the prescription is the product. That sentence describes an incentive in the model. It is no judgment of the people who work there. For you, the incentive matters more than the fee. A business paid on the drug is not paid to spend a quarter finding out why your weight never moved. Its answer to a decade of failed advice is a prescription.

Several of the lowest-priced platforms in that August 2026 chart sold compounded copies. Compounded GLP-1 was legal and common during the 2021–2025 shortage. The shortage has resolved. Large-scale compounding is now restricted. Manufacturers have pursued the remaining sellers in court. The FDA sets out its concerns about unapproved GLP-1 drugs used for weight loss on its own page. Patients who used compounded medication did nothing wrong. GoodLife Health prescribes branded, FDA-approved GLP-1 only. It does so only when a clinician judges one indicated.

Two dated facts show where this part of medicine is heading. In September 2026, Novo Nordisk and Lilly each published self-pay prices for branded medication through NovoCare and LillyDirect. The compounding exception that several low-fee apps were built on has narrowed since the shortage ended. With the branded drug available at a published price, what is left to choose is the clinical work around it. That work means measuring first and following up every quarter.

The app and the membership, priced for year one

Both sides appear below in figures our pricing guides have already published. Each price carries the month it was taken. Prices move, so check the source before you decide.

Year one, both sides

Published prices with the month they were taken

OptionPrice as publishedYear one as publishedLabs in the feeWho earns on the drug
GoodLife Health membership (September 2026)$299 a month$3,588 plus any medication at your pharmacy's own priceFour cardiometabolic panels a yearYour pharmacy. GoodLife Health takes nothing.
GoodLife Health on a branded GLP-1 (September 2026)Roughly $498 to $748 a month all-in$3,588 in fees plus the pharmacy's priceFour cardiometabolic panels a yearYour pharmacy. GoodLife Health takes nothing.
A $99-a-month platform with a compounded drug (August 2026)$298 to $398 a month all-inNot published as a year total in our guidesNot listed in the published priceThe drug is sold inside the price
Compounded-only subscription (September 2026)$300 to $500 a month$3,600 to $6,000None in the feeThe subscription, which sells the drug

On the fee alone, the app is cheaper. That deserves to be said plainly. Once a drug sits inside the price, the published figures move closer together than the adverts suggest. Price is still a poor way to choose between them. The app is built to answer what you should take. The membership is built to find out why first.

GoodLife Health is clinician-led precision direct primary care for cardiometabolic optimization. The order of work is diagnosis first, then treatment, then the long haul. Clinicians are licensed in all 50 states. Your clinician orders a cardiometabolic panel before any treatment decision and orders it again every 90 days, four panels a year. We call each one a Biomarker Audit. Fasting Insulin and Hemoglobin A1c (HbA1c) are read together, so the measuring starts before glucose turns abnormal. Apolipoprotein B (ApoB), Lipoprotein (A) and Hs-CRP are in every panel. TSH With Reflex To Free T4 is drawn every quarter. Every result is in your hands.

Clinical note

A clinician reads Fasting Insulin beside Hemoglobin A1c (HbA1c) in the same quarterly panel. Whether any medication is indicated is decided only after that reading.

The clinician who reads your first panel reads the next one. Between visits, you message the care team asynchronously. Video visits are part of the fee. The point of that continuity is simple. A marker followed over four quarters shows whether what you are doing is working, which a single annual reading cannot show.

If the panel shows that medication is indicated, the clinician prescribes branded, FDA-approved medication to the pharmacy you choose. That pharmacy bills you at its own price. GoodLife Health sets nothing, sees nothing and takes nothing on it. The fee stays $299 whatever is indicated and whatever the dose. If the answer is a lifestyle protocol, the all-in cost is $299 a month. If it is a branded GLP-1, our cost guide puts the all-in at roughly $498 to $748 a month at the manufacturers' published self-pay prices. Through NovoCare, as published in September 2026, Wegovy pens were $199 a month for the first two fills (an introductory offer for new patients through December 2026) and $349 a month after. The Wegovy pill started at $149 a month at lower doses. Through LillyDirect, in the same month, Zepbound vials ran $299 to $449 a month depending on dose.

We call this Medication-Neutral Pricing. It is the integrity argument in this comparison. When the drug is the expensive part, the person prescribing it should earn nothing on it. A prescriber with nothing to gain from a prescription can tell you that a drug is not indicated. Saying so costs that prescriber nothing.

The membership has limits worth knowing before you apply. It does not promise weight loss, remission or a cure. It does not replace insurance. Keep a plan for catastrophic coverage, the hospital and the specialist. The membership pairs with that plan. It does not prescribe without labs. It never prescribes compounded GLP-1. It cannot promise that insurance will cover a medication. That is between you, your plan and your pharmacy. Prior authorization, where a plan requires it, is the pharmacy's process.

GoodLife Health. Medicine that builds on itself, $299 a month: 90-day labs, your clinician, branded GLP-1s, one platform. See if you qualify.GoodLife Health. $299 a month. Everything talks to everything: quarterly labs read by your clinician, branded GLP-1s prescribed from them, every result and dose tracked on one platform. See if you qualify.

What to do this week, whether or not you join

Ask for the number. At your next appointment, ask your clinician to add fasting insulin and Hemoglobin A1c (HbA1c) to the order. Write down each result with its date beside the fasting glucose from the same draw. If your insurer's clinic has a patient portal, download every result from the last decade before you do anything else. Put them in one document in date order. A series is easier to read than any single visit.

If you choose the app, ask four questions before the first payment. Are labs ordered before the prescription? Who reads them? Will the same person read the next set? Does the company earn anything on the medication? The answers will tell you what the fee buys.

We should be honest about what we do not know. Nobody can say what your panel will show before it is drawn. It may show insulin resistance. It may point somewhere else entirely. It may show nothing a drug should treat. Each of those answers is worth more than another year of guessing at a cause you were told was your own.

Who this is not for

This membership is the wrong purchase for some readers. If you want a prescription this week with no labs, the app is built for that and we are not. If the lowest monthly figure decides it, the app's fee is lower than ours. If you are a healthy adult who sees a doctor twice a year and takes no medication, our own cost guide says you will not recoup $3,588. We do not prescribe compounded GLP-1 to anyone. We serve residents of the 50 states only. Not every applicant is accepted. The path is the eligibility check, the intake and the checkout, then a clinician's review.

Here is the offer in plain terms. The membership is $299 a month. At sign-up, $598 is held on your card to cover the first two months. It is a hold that is charged only once a clinician accepts you into care. If the clinician cannot accept you, the hold is released and you are never charged. Once you are accepted, the first two months are charged and are non-refundable. From month three, the membership is month to month. The fee buys four cardiometabolic panels a year, every result in your hands, a clinician who stays, messaging between visits and video visits. When a medication is indicated, it is prescribed to your pharmacy at that pharmacy's price. GoodLife Health takes nothing on it. What the membership returns is the diagnosis a decade of visits never produced, your markers followed over time and an end to the eight-minute visit. It differs from the app in the way that matters most here. It tests first, treats second and sells neither the drug nor the dose. The reason to start now is your own record. You have already given 10 years to advice nobody measured. The first panel turns the next quarter into data.

Related Reading

References

  1. NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
  2. Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
  3. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss